Skip to main content
Median Technologies logo

Median Technologies — Investor Relations & Filings

Ticker · ALMDT ISIN · FR0011049824 LEI · 9695007YG6O07A8N6395 PA Telecommunications, computer programming, consultancy, computing infrastructure, and other information service activities
Open in API
Filings indexed 797 across all filing types
Latest filing 2026-02-18 Regulatory Filings
Country FR France
Listing PA ALMDT

About Median Technologies

https://mediantechnologies.com/

Median Technologies develops and provides innovative imaging solutions and services focused on oncology. The company utilizes proprietary artificial intelligence, computer vision, and signal processing technologies to transform medical images into actionable clinical insights. These insights aid healthcare professionals in the diagnosis, treatment, and monitoring of cancer. Median Technologies serves two primary markets: biopharmaceutical companies, by providing imaging services for oncology clinical trials, and healthcare providers, by offering software for clinical practice, including cancer screening. Its portfolio includes the eyonis® platform, designed for the early detection of cancer.

Recent filings

Filing Released Lang Actions
Inside Information / Other news releases
Regulatory Filings Classification · 85% confidence The document is a press release issued by Median Technologies announcing the appointment of a new President for its U.S. subsidiary and providing updates on the U.S. commercialization strategy for its 'eyonis' software. While it mentions management changes, the primary focus is on the company's operational and commercial strategy following FDA clearance. As it does not fit into specific financial reporting categories like 10-K or IR, and is not a standalone management report or regulatory filing of a specific type, it is best classified as a general regulatory announcement (RNS) which serves as the fallback for corporate press releases of this nature.
2026-02-18 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release from Median Technologies announcing the appointment of a new President for its US subsidiary and detailing the commercial launch strategy for its FDA-authorized product, eyonis LCS. It includes corporate news, strategic updates, and management changes. It does not fit the criteria for a formal financial report (10-K, IR), a transcript (CT), or a specific regulatory filing like a dividend notice. As it is a corporate announcement regarding business operations and management, it falls under the category of general regulatory announcements/corporate news.
2026-02-18 French
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release issued by Median Technologies announcing a commercial distribution agreement with Tempus AI for their medical software, eyonis® LCS. It details the nature of the partnership, the regulatory status of the product, and the strategic implications for both companies. As this is a corporate announcement regarding business operations and partnerships rather than a formal financial report, audit, or regulatory filing, it falls under the general category of regulatory announcements/press releases.
2026-02-12 French
Inside Information / Other news releases
Regulatory Filings Classification · 95% confidence The document is a press release announcing a new commercial distribution partnership between Median Technologies and Tempus AI. It details the nature of the collaboration, the product involved (eyonis LCS), and the strategic goals of the agreement. It does not constitute a formal financial report, audit, or regulatory filing, but rather a corporate announcement regarding business development and operational strategy. As it does not fit into specific categories like M&A (which usually implies a merger or acquisition of the company itself) or Earnings Release, it falls under the general regulatory announcement category for corporate news.
2026-02-12 English
Total number of voting rights and capital / Information on the total number of voting rights and the number of shares making up the capital
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a regulatory disclosure regarding the total number of voting rights and shares in the capital, issued pursuant to French commercial code and AMF regulations. While it mentions voting rights, it is a standard periodic regulatory disclosure of share capital structure rather than a report of specific shareholder meeting results (DVA) or a major shareholding notification (MRQ). As it is a general regulatory announcement required by law, it falls under the RNS category.
2026-02-11 English
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Regulatory Filings Classification · 95% confidence The document is a formal announcement regarding the total number of voting rights and shares composing the capital of Median Technologies as of January 31, 2026. It cites specific French regulatory articles (L.233-8 II of the Commercial Code and 223-16 of the AMF General Regulation) which mandate the disclosure of share capital and voting rights. This type of disclosure is a standard regulatory requirement for listed companies and falls under the category of general regulatory filings/announcements.
2026-02-11 French

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.